Podium to Practice: EHA 2025 – Leukemia: KOMET-007

Podium to Practice: EHA 2025 – Leukemia: KOMET-007

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Julie Bergeron

Icon Chair Speaker

Speakers

Dr. Brian Leber

Dr. Danielle Hammond

Studies / Trials Discussed

S136 – ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION CHEMOTHERAPY (7+3) IN NEWLY DIAGNOSED NPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): UPDATED PHASE 1A/B RESULTS FROM KOMET-007

Studies/trials discussed:

S136 – ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION CHEMOTHERAPY (7+3) IN NEWLY DIAGNOSED NPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): UPDATED PHASE 1A/B RESULTS FROM KOMET-007
Tagged